Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Golidocitinib and Pomalidomide for R/R PTCL
NCT06855823Phase 2Recruiting
- Sponsor
- Sun Yat-sen University
- Start
- Jan 2025
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of golidocitinib in peripheral T-cell lymphoma (PTCL), sponsored by Sun Yat-sen University. Started Jan 2025; status: recruiting.
02
Drugs
golidocitinib
03
Conditions
peripheral T-cell lymphoma (PTCL)
Beyond the preview
Go deeper on NCT06855823.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06855823.